Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat

V. Perlik, A. Kulasekaran, G. Coutinho, M. Votava, JM. Cardot

. 2023 ; 15 (7) : . [pub] 20230701

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015803

Grantová podpora
n.a. Reckitt Benckiser Healthcare Limited

This study aimed to link pharmacokinetic (PK) data from different flurbiprofen preparations for the treatment of sore throat with published data to elucidate whether early efficacy is due to the local action of flurbiprofen or a systemic effect after absorption of the swallowed drug. Three comparative bioavailability studies conducted in healthy subjects provided data from flurbiprofen 8.75 mg formulations, including spray solution, spray gel, lozenges, and granules. A parallel interstudy comparison was made of PK parameters, including partial AUCs (pAUCs), using an ANOVA model with the calculation of 90% confidence intervals (CI) for the differences between least squares (LS) means for each of the test groups versus the respective reference groups. All three studies showed bioequivalence for the respective product comparisons. The interstudy comparison showed a slower rate of absorption for granules compared to spray solution (reference) based on Tmax, Cmax, and pAUCs for 1 h and 2 h. When AUC0.25h and AUC0.5h were considered, slower rates of absorption were also seen for lozenges and spray gel. The differences correlated with the reported time of onset of action, which is faster for the spray solution (20 min) compared to lozenges (26 min) and granules (30 min). These pAUCs provide useful data that allow for the discrimination between formulations. Moreover, the pAUC values represent <5% of the total AUC, suggesting that the early onset of pain relief is a response to immediate local absorption at the site of action rather than a systemic effect.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015803
003      
CZ-PrNML
005      
20231020093523.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics15071863 $2 doi
035    __
$a (PubMed)37514048
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Perlik, Vit $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Albertov 4, 12800 Prague, Czech Republic
245    10
$a Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat / $c V. Perlik, A. Kulasekaran, G. Coutinho, M. Votava, JM. Cardot
520    9_
$a This study aimed to link pharmacokinetic (PK) data from different flurbiprofen preparations for the treatment of sore throat with published data to elucidate whether early efficacy is due to the local action of flurbiprofen or a systemic effect after absorption of the swallowed drug. Three comparative bioavailability studies conducted in healthy subjects provided data from flurbiprofen 8.75 mg formulations, including spray solution, spray gel, lozenges, and granules. A parallel interstudy comparison was made of PK parameters, including partial AUCs (pAUCs), using an ANOVA model with the calculation of 90% confidence intervals (CI) for the differences between least squares (LS) means for each of the test groups versus the respective reference groups. All three studies showed bioequivalence for the respective product comparisons. The interstudy comparison showed a slower rate of absorption for granules compared to spray solution (reference) based on Tmax, Cmax, and pAUCs for 1 h and 2 h. When AUC0.25h and AUC0.5h were considered, slower rates of absorption were also seen for lozenges and spray gel. The differences correlated with the reported time of onset of action, which is faster for the spray solution (20 min) compared to lozenges (26 min) and granules (30 min). These pAUCs provide useful data that allow for the discrimination between formulations. Moreover, the pAUC values represent <5% of the total AUC, suggesting that the early onset of pain relief is a response to immediate local absorption at the site of action rather than a systemic effect.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kulasekaran, Anuradha $u Reckitt Healthcare Limited, 103-105 Bath Road, Slough, Berkshire SL1 3UH, UK
700    1_
$a Coutinho, Graça $u Reckitt Healthcare Limited, 103-105 Bath Road, Slough, Berkshire SL1 3UH, UK
700    1_
$a Votava, Martin $u Cadore INV Scientific Consultant, Akademicka 1, 10800 Prague, Czech Republic $1 https://orcid.org/0009000955924722
700    1_
$a Cardot, Jean-Michel $u SAS BORVO Consultant, 18 Av de Charade, 63122 Ceyrat, France
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 15, č. 7 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37514048 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093517 $b ABA008
999    __
$a ok $b bmc $g 1997272 $s 1202165
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 7 $e 20230701 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a n.a. $p Reckitt Benckiser Healthcare Limited
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...